AOD-9604 guide & protocols

AOD-9604 has a more interesting story than most compounds on this site, and you should know it before you read the dosing. It was engineered to be a diet drug, taken all the way into human testing by a real pharmaceutical company, and then abandoned, because in people it did not do enough. Everything below sits on top of that fact. What circulates now is a community practice built around a compound the evidence declined to endorse for its original purpose, and a joint-health angle that has quietly outlasted the fat-loss one.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target amount you're working with.

What it is

AOD-9604 is a short piece of human growth hormone, sixteen amino acids taken from the tail end of the molecule, with one small modification to help it survive. The idea behind it was elegant. Growth hormone does several things at once, and one of them is telling fat cells to release their contents. The rest of what it does, including making you less sensitive to insulin, is unwanted if fat is all you're after. So Australian researchers cut out the part that handles fat and left the rest behind.

That's why it doesn't behave like the other compounds in this family. It doesn't attach to the growth hormone receptor and it doesn't raise IGF-1, so none of the growth signalling happens. It's a fragment doing one job. It also carries an unusual regulatory footnote: it holds a US food-ingredient safety designation, which is not a drug approval and is often misrepresented as one.

What people use it for

Fat loss is the reason most people arrive, specifically the hope of something that mobilises fat without touching blood sugar or appetite. That's an appealing proposition for anyone who found the GLP-1 compounds too blunt or too hard on the stomach, and it's what the compound was built to do.

Joints are the reason a lot of people stay. The cartilage work is genuinely interesting, it came later than the fat research, and it's the direction interest has drifted as the fat-loss case weakened. People also pair it with recovery compounds for that reason rather than the metabolic one. Both threads are covered below, and it's worth knowing which one you're actually here for, because they point at different amounts and different expectations.

Formulations

AOD-9604 ships as a lyophilized powder for subcutaneous injection. Across the vendors we track, 5 mg vials are by far the most common, with 10 mg the usual alternative and 2 mg still available from a few. Because the amounts people run are measured in micrograms, a single vial goes a long way, which makes this one of the cheaper compounds to actually run despite a mid-range per-milligram price.

Oral versions circulate, and they carry a real historical claim: this compound was studied as an orally active one, which is rare for a peptide and was a large part of its original commercial appeal. What that research established was that something measurable happened when it was given by mouth in animals. It did not establish that any particular oral product sold today delivers a comparable amount, and there's no way to check that from the outside.

Dosing protocols

Unlike tesamorelin or semaglutide, there is no approved product here and no label to copy, so every pattern below is convention rather than instruction. The one thing that does trace to real human research is the last row, and it's the row worth reading twice.

See the AOD-9604 research notes for the underlying research behind these figures.

All patterns above are subcutaneous injection, commonly into abdominal fat.

What that last row means for the rest of the table

It doesn't mean the compound does nothing. The animal research is consistent and the mechanism holds up, and there's a real difference between "we found nothing" and "we didn't find enough to justify the cost of getting a drug approved." But it does mean that the 300 mcg figure everyone repeats has no human trial behind it. It's a number the market settled on, and it has been repeated often enough to feel established. Treat it as convention, because that's what it is.

Amount total, for planning your vial purchase: at 300 mcg daily a 5 mg vial holds sixteen doses with 200 mcg left over (5,000 divided by 300 is 16 with a remainder), so about two and a half weeks. A twelve-week stretch runs 25.2 mg (300 mcg times 84 days), which is five of those vials. Compare vendors against a figure like that.

How much to reconstitute at once: a reconstituted vial keeps about 28 days refrigerated, and at 300 mcg daily that window uses 8.4 mg. So a 5 mg vial comfortably fits inside it and can be mixed whole, while a 10 mg vial does not, and mixing one in full means throwing away roughly a sixth of it. Working example: 5 mg into 2 mL of bacteriostatic water gives 2,500 mcg per mL, so 300 mcg is 300 divided by 2,500, times 100, which is 12 units on a standard U-100 insulin syringe. See how much to reconstitute at once for the general math.

Cycling guidelines

Twelve weeks on, with a break of several weeks after, is the pattern most commonly described, and there's nothing published establishing either the length or the break. The reasoning offered is that the fat-mobilising effect is thought to work partly by increasing the number of receptors fat cells use to release their contents, and that continuous stimulation might blunt that. It's a plausible-sounding argument built on animal work, not a tested schedule.

Where it's run for joints rather than fat, longer continuous stretches are described instead, on the reasoning that tissue repair is a slower process than fat mobilisation. Same absence of evidence, different guess.

Signs a course is commonly stopped or reconsidered:

• Injection site reactions that don't settle between daily doses
• Headaches or a persistent feeling of being off, which are the most commonly reported complaints and are usually mild
• Twelve weeks with no change of any kind, which is the most common reason people stop and worth naming plainly given how much of the case here rests on animal research

Stacking

Most commonly paired stack: AOD-9604 with BPC-157.

Rationale: this is the joint and tissue pairing rather than the fat one, and it's the stack that reflects where interest in this compound has actually gone. The argument is that one supports cartilage and the other supports the surrounding soft tissue, addressing a joint problem from two directions.

Protocol as run: both dosed once daily, run on the same schedule for the same stretch, as separate injections. Timing isn't matched to anything in particular, since neither compound has a meal or sleep dependency the way the growth hormone secretagogues do.

Lighter stacks: the growth hormone secretagogues, CJC-1295 and Ipamorelin, come up on the fat side. The pairing rationale is that AOD-9604 mobilises fat while the secretagogues raise growth hormone more broadly, though it's worth noticing that AOD-9604 exists precisely to avoid the growth hormone effects those compounds are producing, so the combination somewhat argues against itself. Semaglutide shows up as an appetite-plus-mobilisation pairing, with no combination data.

Combinations to approach carefully: nothing here has a specific interaction warning attached, which is less reassuring than it sounds. It reflects the absence of human study rather than a clean safety record, and that distinction is worth holding onto.

Expected results timeline

Early weeks: nothing, generally. There's no acute effect people report the way they report sleep changes on a growth hormone secretagogue or appetite changes on a GLP-1, which makes the first few weeks feel like nothing is happening because as far as anyone can tell, nothing noticeable is.

Months in: where change is reported, it's described gradually and modestly over a twelve-week stretch, and it's self-reported rather than measured. On the joint side, people describe improvement over a similar timeframe.

Extended, continued use: no long-run human data exists in either direction. The animal research ran weeks, not years.

What to expect realistically: this is the compound on this page where the honest answer is the least satisfying. The human research that was run for weight was not encouraging enough to continue, and a company that had spent years and real money on it walked away. That is the single most informative fact available, more informative than any amount of favourable animal work, and anyone running this for fat loss should size their expectations to it. The joint case is genuinely more open, but it rests on animal work too and no human trial has been published.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target daily amount.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe, which matters here more than usual, because at 12 units a standard syringe is the only practical way to measure the amount accurately.
4. A subcutaneous site in the abdomen is chosen, with sites rotated daily.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. The dose is commonly given in the morning before eating, on the reasoning that insulin from a meal works against fat mobilisation.

Side effects and safety

Common: very little is reported, and what there is tends to be injection site reactions and occasional headaches. This compound's tolerability is genuinely one of the better things about it, and it's consistent with the mechanism, since the growth hormone effects that cause most of the trouble in this category aren't happening.

Less common: nothing consistently reported. The absence of a blood sugar effect is the notable one, and it's the thing the compound was designed to achieve.

What we don't know: more than usual, and in an unusual direction. Human research was run, which is rare here, but it was run for a specific purpose and it stopped, so there is no long-run human safety record and no data at all in people using it the way it's used now. The joint application has never been tested in a person. The food-ingredient safety designation covers a food ingredient at food-ingredient quantities and says nothing about injecting it daily for months.

Contraindications: pregnancy, breastfeeding, and use in minors have no data behind them. Active cancer is the caution carried across this whole family on general principle, though the usual reasoning for it, growth signalling, applies less here than to the rest of the category.

Drug interactions: none established. Read that as an absence of study rather than a clean bill.

AOD-9604 vs. Tesamorelin

Tesamorelin is the natural comparison, because both are derived from growth hormone and both are used against abdominal fat, and they represent the two opposite ends of the evidence spectrum on this site.

Choose AOD-9604 if: the joint angle is what interests you, or you want something inexpensive and very well tolerated and you're clear-eyed that the fat-loss case did not survive human testing.

Choose tesamorelin if: abdominal fat is the actual target and you want the compound with real published evidence behind it, and the daily cost and the blood sugar monitoring are acceptable.

See the Tesamorelin research notes for its own background and pricing, and the tesamorelin guide and protocols for its dosing.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C and protect from light. This compound is commonly described as more forgiving than most about brief periods at room temperature, though lot-specific stability should come from the vendor's certificate of analysis rather than a general rule.

Reconstituted solution: refrigerate and use within about 28 days, the standard window for a bacteriostatic-water solution. At the amounts people run, a 5 mg vial fits comfortably inside that window and a 10 mg vial does not. Avoid repeated freeze-thaw cycles.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or the reconstituted liquid
• Powder that has clumped or gone sticky, which usually means moisture reached it

FAQ

Is it FDA-approved? No. It holds a US food-ingredient safety designation, which is not a drug approval and is regularly misrepresented as one on vendor pages.

How much do people run? 300 mcg once daily, in the morning before eating, is what circulates almost universally. It's convention, not a trial figure.

Does it actually work for fat loss? The animal research is consistent. The human research for weight was not encouraging enough to continue and development stopped, which is the most important thing to know before spending money on it.

What about the joint use? The cartilage work is real and interesting and has only been done in animals. No human trial has been published.

Does it affect blood sugar? It's specifically designed not to, which is the whole reason the fragment was cut out of the larger molecule.

Can I take it orally? It was studied as an orally active compound, unusually for a peptide. Whether any oral product sold today delivers a comparable amount is not something you can verify.

How long do people run it? Twelve weeks with a break after is the common pattern. Longer continuous stretches are described where it's being run for joints.

How is it stored? Refrigerated and out of the light, and used within about 28 days once reconstituted.

Bottom line

Key dosing takeaways:

• 300 mcg once daily in a fasted morning is what circulates, and it is convention rather than a figure from any human study
• The compound was tested in people for weight and abandoned when the effect was too small, and every dosing pattern here sits on top of that fact
• Microgram dosing means a 5 mg vial covers about two and a half weeks, which makes this cheap to actually run

Best practices:

• Reconstituting a 5 mg vial rather than a 10 mg one avoids wasting material the 28-day window can't reach
• Deciding upfront whether you're here for fat or for joints, since the two threads have different evidence and different expectations
• Giving it a defined stretch with a decision point at the end, rather than running it indefinitely on hope

Works best for people who:

• Are interested in the joint and cartilage angle, where the case is more open
• Want something very well tolerated that leaves blood sugar and appetite alone
• Can hold two things at once: that the mechanism is real and that the human weight-loss case did not hold up

AOD-9604 is sold for research, and the human research that exists is the reason a pharmaceutical company stopped working on it. You already know that. You're an adult making an informed call about your own body, and that's yours to make.